Question-and-Answer Session
Operator
(Operator instructions) Your first question comes from Brian Abrahams from Oppenheimer and Company.
Brian Abrahams – Oppenheimer & Co.
Taking a step back in the hep C space, obviously INFORM I looks very promising. It seems like there’s probably going to be a lot of others who are going to follow your lead and develop STAT-C combos, so beyond being one of the furthest along with such paradigm, how should we be thinking about in terms of what could be the most differentiating aspect of the 191-7128 combo compared to other combos that might ultimately also reach the market?
Dan Welch
I’ll have Scott Seiwert handle that question. Others will add to it as we see fit.
Scott Seiwert
We do believe that we are at the cusp of a potentially a very important change in treatment of HCV. One that’s more convenient, one that is more efficacious, and also one that is displaying better safety. There are going to be many players that would like to get into the space. We’re very happy with the combination that we’re advancing in collaboration with our partners, Roche and Pharmasset, and I think to the point of your question that a combination of a nucleotide inhibitor of the polymerase and the protease of HCV is particularly attractive to us. The nucleoside in particular displays a high genetic barrier which we believe will be crucial to provide a resistance barrier that will provide a narrow escape as we use directed anti-virals against the virus and the absence of interferon. So combined with the safety profile of the compounds as now have been demonstrated in numerous clinical studies, we believe that the efficacy, the barrier to resistance, and the safety together combine to make this a particularly attractive combination, and one that we know the most about relative to these other potentials.
Brian Abrahams – Oppenheimer & Co.
Anytime timeline for the results of the ritonavir combo study?
Dan Welch
No we haven’t disclosed that Brian.
Operator
Your next question comes from the line of Terence Flynn – Lazard Capital Markets.
Terence Flynn – Lazard Capital Markets
On the NDA for pirfenidone, I was wondering if you can confirm if you requested priority review?
Dan Welch
Yes, we have.
Terence Flynn – Lazard Capital Markets
And when might you expect to hear back from FDA if they’ve accepted it for priority review?
Dan Welch
- To read the full transcript on Seeking Alpha, click here »
